AJR. American journal of roentgenology
-
AJR Am J Roentgenol · Dec 2007
Randomized Controlled Trial Multicenter StudyCT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). ⋯ The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.
-
AJR Am J Roentgenol · Nov 2007
Multicenter StudyDiagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial.
The purpose of this study was to compare gadobenate dimeglumine-enhanced MR angiography and unenhanced time-of-flight MR angiography for the detection of significant peripheral arterial occlusive disease using digital subtraction angiography as our reference standard. ⋯ Improved diagnostic performance and reproducibility are achievable with gadobenate dimeglumine-enhanced MR angiography in patients with peripheral arterial occlusive disease.
-
AJR Am J Roentgenol · Jun 2007
Multicenter StudyImaging-guided bone biopsy for osteomyelitis: are there factors associated with positive or negative cultures?
The objective of our study was to identify the clinical and technical factors associated with positive or negative culture results in histologically positive cases of osteomyelitis obtained from imaging-guided bone biopsies. ⋯ The rate of positive culture results in histologically proven cases of osteomyelitis obtained from imaging-guided bone biopsies is low. Aspirating > or = 2 mL of purulent fluid is associated with a significantly higher rate of positive cultures.
-
AJR Am J Roentgenol · Sep 2004
Multicenter StudyIncrease in utilization of percutaneous renal artery interventions by medicare beneficiaries, 1996-2000.
Our purpose was to review data from Medicare physician claims to ascertain differences in annual volumes of renal artery interventions versus surgery and differences in utilization of renal artery interventions among geographic regions according to physician provider type between 1996 and 2000. ⋯ Among Medicare beneficiaries, the volume of percutaneous renal artery interventions is increasing rapidly, whereas the volume of renal artery surgery is declining. Most growth in percutaneous renal artery revascularization is attributed to increased performance by cardiologists; explosive growth in annual procedure volume by cardiologists occurred in some regions. Marked disparity in use among CMS regions was found.
-
AJR Am J Roentgenol · Sep 2003
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialGadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
The purpose of this study was to evaluate the clinical efficacy and dose response relationship of three doses of gadobenate dimeglumine for MRI of the breast and to compare the results with those obtained after a dose of 0.1 mmol/kg of body weight of gadopentetate dimeglumine. SUBJECTS AND METHODS. Gadobenate dimeglumine at 0.05, 0.1, or 0.2 mmol/kg of body weight or gadopentetate dimeglumine at 0.1 mmol/kg of body weight was administered by IV bolus injection to 189 patients with known or suspected breast cancer. Coronal three-dimensional T1-weighted gradient-echo images were acquired before and at 0, 2, 4, 6, and 8 min after the administration of the dose. Images were evaluated for lesion presence, location, size, morphology, enhancement pattern, conspicuity, and type. Lesion signal intensity-time curves were acquired, and lesion matching with on-site final diagnosis was performed. A determination of global lesion detection from unenhanced to contrast-enhanced and combined images was performed, and evaluations were made of the diagnostic accuracy for lesion detection and characterization. A full safety evaluation was conducted. ⋯ Gadobenate dimeglumine is a capable diagnostic agent for MRI of the breast. Although preliminary, our results suggest that 0.1 mmol/kg of gadobenate dimeglumine may offer advantages over doses of 0.05 and 0.2 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadopentetate dimeglumine for breast lesion detection and characterization.